TheraCryf (formerly known as Evgen Pharma) is a company that develops therapeutics for oncology and behavioral brain disorders. Its pipeline includes clinical and preclinical therapies for conditions such as neurodevelopmental disorders, glioblastoma, addiction, anxiety, fatigue, and narcolepsy. The company utilizes Sulforadex technology to stabilize and synthesize sulforaphane analogs. TheraCryf caters to mid-size and large pharmaceutical companies.